Stay updated on Pfizer Press Releases
Sign up to get notified when there's something new on the Pfizer Press Releases page.

Latest updates to the Pfizer Press Releases page
- ChecktodayChange DetectedNew archive entries for February 2026 and December 16, 2025 were added, including 'Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance' and 'Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial'. The archive also removes the December 16 webcast invitation and the 11.21.2025 entry announcing that PADCEV plus Keytruda received FDA approval for certain bladder cancer patients.SummaryDifference8%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a new press release entry: 'Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer' (01.10.2026) under Medicines. Removed the item 'Pfizer Completes Acquisition of Metsera' (11.13.2025) from Corporate.SummaryDifference2%

- Check29 days agoChange DetectedJanuary 2026 entries (01.05.2026) were added to the Press Release Archive, and the 11.12.2025 entry was removed. The archive now reflects the latest releases for the start of 2026.SummaryDifference2%

- Check43 days agoChange DetectedAdded three December 2025 press releases to the Pfizer Press Release Archive and removed three November 2025 entries.SummaryDifference8%

- Check50 days agoChange DetectedDecember 2025 press releases were added to the archive (Pfizer Declares First-Quarter 2026 Dividend; TUKYSA maintenance therapy update; Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma), and October 2025 items were removed from the archive.SummaryDifference7%

- Check57 days agoChange DetectedAdded a new press release entry under Prescription Medicines for HYMPAVZI® (marstacimab) dated 12.06.2025. Removed the 'Research and Pipeline' category and the press release 'XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer' dated 10.19.2025.SummaryDifference1%

Stay in the know with updates to Pfizer Press Releases
Enter your email address, and we'll notify you when there's something new on the Pfizer Press Releases page.